Clinical Development Progress of VSA012, an siRNA Molecule Targeting CFB

• VSA012 profile, a highly potent and selective inhibitor of CFB
• Phase 2 data of in PNH in naïve and refractory patients
• Preliminary data in IgAN for VSA012

NEW SPEAKING COMPANY

Speakers:

Xiaoming Zou

Chief Executive Officer

Visirna Therapeutics